Advanced Search

 

Study ID Status Title Patient Level Data
MET111646 Completed A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Study Listed on ClinicalStudyDataRequest.com
MET111647 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MET111648 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects with Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MKI102428 Completed A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD) Study Listed on ClinicalStudyDataRequest.com
MKI106209 Completed A randomised, double-blind, placebo-controlled parallel study to assess the safety, tolerability,pharmacodynamics and steady state pharmacokinetics of repeated doses of GW856553 in patients with COPD
MOT107043 Completed A First-Time-in-Human Randomized Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of the Oral Motilin Receptor Agonist GSK962040, in Male and Female Healthy Subjects Study Listed on ClinicalStudyDataRequest.com
MOT109681 Completed A randomized, double-blind, ascending dose trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, of repeat doses of motilin receptor agonist GSK962040 in male and female healthy volunteers Study Listed on ClinicalStudyDataRequest.com
MT400-101 (112490) Completed A study to evaluate the bioavailability of combo formulation, each of its components and currently marketed versions of the components in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MT400-102 (112491) Completed A study to evaluate the effect of food on the bioavailability of a sumatriptan succinate and naproxen sodium combination tablet in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MT400-103 (112492) Completed A study to evaluate the bioavailability of different dose combinations of sumatriptan succinate and naproxen sodium 500 mg in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MT400-104 (112493) Completed An open-label study to investigate the effect of migraine attacks on the pharmacokinetics of a single dose of Treximet™ (formerly known as Trexima™) administered both during and outside of a migraine attack Study Listed on ClinicalStudyDataRequest.com
MT400-105 (112494) Completed A study to evaluate the pharmacokinetics and tolerability of two single Treximet™ (formerly known as Trexima™) tablets (administered two hours apart) in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
NAI30008 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study To Investigate The Efficacy And Safety Of Zanamivir (GG167) 10mg Administered Twice A Day For Five Days In The Treatment Of Influenza In Patients 12 Years Or Over With Asthma Or Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
NAI30009 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5-12. Study Listed on ClinicalStudyDataRequest.com
NAI30010 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families. Study Listed on ClinicalStudyDataRequest.com
NAI30011 Completed A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Impact of Inhaled Zanamivir Treatment on Workplace Attendance Due to Influenza A and B Infections Study Listed on ClinicalStudyDataRequest.com
NAI30012 Completed A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged >= 65 Years. Study Listed on ClinicalStudyDataRequest.com
NAI30015 Completed A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel. Study Listed on ClinicalStudyDataRequest.com
NAI30020 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice a Day for Five Days in the Treatment of Symptomatic influenza A and B Viral Infections in High Risk Patients Study Listed on ClinicalStudyDataRequest.com
NAI30028 Completed A Double-Blind,Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Twice a Day for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Children. Study Listed on ClinicalStudyDataRequest.com
NAI30031 Completed A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day for 10 Days in the Prevention of Transmission of Symptomatic Influenza A and B Viral Infections within Households Study Listed on ClinicalStudyDataRequest.com
NAI30034 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community-Dwelling High-risk … Study Listed on ClinicalStudyDataRequest.com
NAIA1001 Completed A Study to Investigate the Effect of Intranasal GR121167X on Infection Rates in Healthy Male Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) virus Study Listed on ClinicalStudyDataRequest.com
NAIA1002 Completed A Study to Investigate the Effect of Intranasal GG167 Initiated at Various Intervals Post Inoculation on Infection in Healthy Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus Study Listed on ClinicalStudyDataRequest.com
NAIA1003 Completed A Study to Investigate the Effect of Intranasal GG167 at Various Dosing Frequencies on Infection in Healthy Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.